SEC Form 4 · accession 0001144204-15-037773

INTERCEPT PHARMACEUTICALS, INC. · ICPT

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — CMO and EVP - Development

Period of report

Jun 15, 2015

Accepted (ET)

Jun 17, 2015 · 9:00 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001270073

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock	Jun 15, 2015	M	3,500	$8.6667	A	22,014	D
Common Stock^F3	Jun 15, 2015	S	1,600	$241.0313	D	20,414	D
Common Stock^F4	Jun 15, 2015	S	1,900	$242.0505	D	18,514	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Option to Purchase Common Stock^F2	$8.6667	Jun 15, 2015	M	3,500	D	—	Aug 16, 2020	Common Stock	3,500	26,294	D

F1The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on November 25, 2014.
F2All shares underlying this option have vested.
F3This transaction was executed in multiple trades at prices ranging from $241.0000 to $241.5000. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F4This transaction was executed in multiple trades at prices ranging from $242.0000 to $242.3200. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.